A Study of SGB-7342 in Subjects With Obesity or Overweight
A Phase 1, Randomized, Double-blind, Placebo-controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SGB-7342 in Subjects With Obesity or Overweight
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: SGB.clinical
- Phone Number: +086 021-60209828
- Email: SGB.clinical@sanegenebio.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Body Mass Index (BMI) within the range of 26.0 to 35.0 kg/m²
- Have a stable body weight within 3 months
- Participants must agree to use adequate contraception from signing the informed consent until 6 months after completion of the follow-up visit.
- Willing to comply with the protocol required visit schedule and visit requirements and provide written informed consent.
Exclusion Criteria:
- A history of or a current surgical or medical condition that, in the opinion of the Investigator, may put the subject at significant risk (according to Investigator's judgment) or interfere with the subject's participation in the clinical study.
- Use of GLP-1R agonists for any indication within 6 months prior to administering the investigational drug.
- Use of non-GLP1R medications for weight loss within 3 months prior to administering the investigational drug.
- Alanine aminotransferase (ALT), total bilirubin (TBIL), aspartate aminotransferase (AST)> 1.5 × ULN, and deemed clinically significant by the Investigators
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: SGB-7342
|
SC injection, single dose
|
|
Placebo Comparator: SGB-7342-Matching placebo
|
Normal saline (0.9% NaCl) in a matching volume, SC injection, single dose
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of Participants with Adverse Events (AEs)
Time Frame: up to approximately 6 months
|
up to approximately 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Maximum Observed Plasma Concentration (Cmax)
Time Frame: up to approximately 3 days
|
up to approximately 3 days
|
|
Area Under the Concentration-time Curve (AUC)
Time Frame: up to 3 days
|
up to 3 days
|
|
Weight change from baseline
Time Frame: up to approximately 12 months
|
up to approximately 12 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SGB-7342-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.